AIM:To observe the clinical therapeutic efficacy and safety of intravitreal injection of Ranibizumab for choroidal neovascularization(CNV)in patients with non age-related macular degeneration(non-AMD).

METHODS:Continous cases that had been diagnosed as CNV in non-AMD patients from July 2011 to October 2015 and accepted intravitreal injection of ranibizumab were retrospective analyzed for the efficacy and systemic adverse reactions. The slit lamp examination, best-correct visual acuity(BCVA), fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were conducted before and after treatment. the injection number, BCVA and the central macular thickness(CMT)within diameter of 1mm at macula before and after treatment were observed.

RESULTS:The follow-up duration was 6mo to 3a in total 22 patients with 24 eyes. The BCVA was 4.50±0.34 at baseline and was improved significantly to 4.77±0.24 after treatment(P<0.01). Mean CMT decreased from 421.63±139.37μm at baseline to 317.62±55.05μm at the final follow-up(P<0.01). The average injection number was 2.6±1.3. None ocular complications and systematic side effects were observed in all cases, such as endophthalmitis, glaucoma, retinal detachment or uveitis.

CONCLUSION:The intravitreal injection of ranibizumab for CNV in non-AMD patients is effective with few side effects.